Physician profile
Arbus E Locklear
NPI 1982697355
$11,038.98
in general payments reported to CMS, 2019-2025
44 companies · $2,317 in 2025
The $2,317 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,770 · 2022: $2,533 · 2023: $2,090 · 2024: $2,329 · 2025: $2,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,704 · Education: $31.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,704.30 |
| Education | $31.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,863.64 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,426.58 | 2021-2025 | |
| Novo Nordisk INC | $1,089.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,080.58 | 2021-2025 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $826.45 | 2022-2025 | |
| Lilly USA, LLC | $685.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $580.06 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ironwood Pharmaceuticals, INC | $284.56 | 2021-2024 | Linzess |
| Merck Sharp & Dohme LLC | $264.82 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.56 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.36 | 2021-2025 | Xifaxan, Trulance |
| Paratek Pharmaceuticals, INC. | $226.43 | 2021-2025 | Nuzyra, Xhance |
| Idorsia Pharmaceuticals US INC | $224.40 | 2022-2024 | Quviviq |
| Pfizer INC. | $222.63 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.46 | 2022-2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $154.84 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $151.12 | 2021-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $143.58 | 2021-2022 | |
| Corcept Therapeutics | $134.80 | 2024-2025 | Korlym |
| Biohaven Pharmaceutical Holding Company Ltd. | $123.21 | 2022 | |
| Esperion Therapeutics, INC. | $104.17 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $75.24 | 2021-2024 | |
| Forte Bio-Pharma LLC | $73.73 | 2022-2024 | Prolate, Nalocet |
| Amarin Pharma, INC. | $71.42 | 2021-2022 | |
| Eisai INC. | $61.78 | 2021-2022 | |
| Exact Sciences Corporation | $48.08 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $40.92 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $40.11 | 2021 | |
| Abbott Laboratories | $39.73 | 2024-2025 | Octrode, Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $35.26 | 2025 | Symbravo |
| Mylan Specialty L.P. | $34.21 | 2021 | |
| Horizon Therapeutics Plc | $33.67 | 2022-2023 | Krystexxa |
| Redhill Biopharma INC. | $26.16 | 2021 | |
| Lundbeck LLC | $25.24 | 2025 | Rexulti |
| Viatris Specialty LLC | $24.90 | 2025 | Yupelri |
| Ardelyx, INC. | $24.15 | 2024 | Ibsrela |
| Almatica Pharma LLC | $20.99 | 2023 | Loreev Xr |
| Dexcom, INC. | $17.97 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $17.58 | 2023 | Xarelto |
| Avanir Pharmaceuticals, INC. | $17.44 | 2021 | |
| Daiichi Sankyo INC. | $17.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.59 | 2021 | |
| Allergan, INC. | $12.20 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arbus Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.